Best Healthcare Stocks to Buy Right Now for Long-Term Growth

The article highlights two healthcare names—HCA Healthcare and Abbott Laboratories—as long-term buy candidates based on durable demand and strong competitive moats. HCA is praised for its diversified U.S. network, entrenched payer relationships and recent strong financial results but faces reimbursement and regulatory risk. Abbott is noted for durable innovation (FreeStyle Libre CGM with large global upside), patent-backed pricing power and reliable capital returns—it's a Dividend King with 50+ consecutive annual payout increases. Both names are framed as long-duration holdings rather than near-term catalysts.

Analysis

Volume growth from demographic trends is necessary but not sufficient — the near-term driver will be who converts that demand into durable, higher-margin cashflows. Hospital operators with scale can squeeze incremental margin by centralizing staffing, supply procurement and IT, but labor cost inflation and rising capital intensity for digital/AI platforms mean margin gains require 12–36 months to realize and are sensitive to wage cycles and interest rates.

For device franchises tied to consumables, unit economics behave like annuities: each incremental patient using a CGM system sustains recurring revenue and widens switching costs. That makes upstream supply-chain bottlenecks (sensor substrates, adhesives, ASIC supply) an underappreciated lever — shortages or supplier consolidation can temporarily boost margins and pricing power for incumbents for 6–18 months, while patent losses or payer coding changes can compress them over a 3–5 year horizon.

Key catalysts to watch over the next 90–180 days are pricing/reimbursement guidance, component-supply announcements, and Q1 results that quantify utilization, same-store procedure growth, and margin cadence. Tail risks that would rapidly reverse value include abrupt Medicare/DRG reimbursement cuts, a meaningful patent challenge in flagship device lines, or a macro shock that slashes elective procedures — each could erase 20–40% of implied value within months if realized.

Key Decisions for Investors

• Buy ABT stock as a core 12–36 month holding and improve entry via an options collar: buy 1000 shares ABT or equivalent notional + buy 12-month 15% OTM puts and sell two 6–9 month covered calls to fund ~60–80% of put cost. Risk/reward: target +35–50% upside in 12–36 months if CGM adoption and margin expansion sustain; downside capped to ~15–20% (net of premiums) versus outright stock exposure.
• Relative-value pair: go long ABT / short HCA (notional short ~50% of long) for 12 months to exploit secular annuity-like growth vs cyclical margin exposure. Thesis: ABT > HCA by 15–25% total-return over 12 months if CGM supply/demand and pricing hold; tail risk is regulatory reimbursement favoring hospitals — stop-loss: unwind if HCA outperformance >10% vs ABT within 60 days.
• If holding HCA, buy 6–12 month protection: purchase 15% OTM puts to limit downside from a reimbursement shock. Expected cost: ~1–3% of notional; risk/reward: preserves upside participation while capping policy/litigation tail losses at a manageable premium.
• Event trade: monitor supplier-sourced supply disruptions or positive reimbursement code rulings; if announced favorably for device consumables, switch a portion of cash from HCA to ABT or increase ABT call spread exposure (12–24 month 20–35% OTM call vertical) to capture asymmetric upside from transient margin expansion.